Morgan Stanley’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-14,503
| Closed | -$72.7K | – | 8249 |
|
|
2024
Q3 | $72.7K | Buy |
14,503
+8,384
| +137% | +$54.4K | ﹤0.01% | 6111 |
|
|
2024
Q2 | $40.4K | Buy |
6,119
+5,574
| +1,023% | +$37.9K | ﹤0.01% | 6236 |
|
|
2024
Q1 | $5.99K | Sell |
545
-419
| -43% | -$4.54K | ﹤0.01% | 6845 |
|
|
2023
Q4 | $13K | Buy |
964
+629
| +188% | +$10.2K | ﹤0.01% | 6776 |
|
|
2023
Q3 | $7.28K | Sell |
335
-18
| -5% | -$577 | ﹤0.01% | 6822 |
|
|
2023
Q2 | $13.6K | Sell |
353
-150
| -30% | -$5.29K | ﹤0.01% | 6696 |
|
|
2023
Q1 | $13.9K | Buy |
503
+442
| +725% | +$15K | ﹤0.01% | 6757 |
|
|
2022
Q4 | $2.01K | Sell |
61
-243
| -80% | -$17.7K | ﹤0.01% | 7373 |
|
|
2022
Q3 | $37K | Sell |
304
-217
| -42% | -$39.1K | ﹤0.01% | 6551 |
|
|
2022
Q2 | $91K | Buy |
521
+307
| +143% | +$64.7K | ﹤0.01% | 6326 |
|
|
2022
Q1 | $62K | Sell |
214
-14
| -6% | -$5.31K | ﹤0.01% | 6604 |
|
|
2021
Q4 | $120K | Buy |
228
+51
| +29% | +$36.6K | ﹤0.01% | 6334 |
|
|
2021
Q3 | $68K | Sell |
177
-26
| -13% | -$11.1K | ﹤0.01% | 6579 |
|
|
2021
Q2 | $181K | Buy |
203
+106
| +109% | +$81.1K | ﹤0.01% | 6067 |
|
|
2021
Q1 | $117K | Sell |
97
-23
| -19% | -$31.7K | ﹤0.01% | 5930 |
|
|
2020
Q4 | $160K | Buy |
120
+118
| +5,900% | +$173K | ﹤0.01% | 5705 |
|
|
2020
Q3 | $5K | Buy |
+2
| New | +$4.52K | ﹤0.01% | 6458 |
|
Morgan Stanley's BIOR Position: Q4 2024 in Review
Morgan Stanley sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q4 2024, closing a stake of 14,503 shares — an estimated $72.7K sold.
Morgan Stanley first reported a position in BIOR in Q3 2020 and held it in 17 quarters. The position peaked at $181K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOR as of Q4 2024.
- Morgan Stanley reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Morgan Stanley sold 14,503 Biora Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $72.7K.
- Morgan Stanley first reported a position in Biora Therapeutics, Inc. Common Stock in Q3 2020 and held it in 17 quarters.
- Morgan Stanley's Biora Therapeutics, Inc. Common Stock position peaked at $181K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q4 2024.
Based on Morgan Stanley's 13F filing for Q4 2024, filed 14 Feb 2025.